Evidence map›Paper›PMID 42396832›Full record

ArticleThe Cochrane database of systematic reviews2026

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

Allison Mo, Matthew Poynton, Catherine Kimber, Mario Csenar, Carolyn Dorée, Catherine Prodger, Simon Stanworth, Zoe McQuilten

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Allison MoTransfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia.
Matthew PoyntonDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Catherine KimberSystematic Review Initiative, NHS Blood and Transplant, Oxford, UK.ORCID https://orcid.org/0000-0002-7796-9931
Mario CsenarInstitute of Public Health, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
Carolyn DoréeSystematic Review Initiative, NHS Blood and Transplant, Oxford, UK.
Catherine ProdgerDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Simon StanworthDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Zoe McQuiltenTransfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of both supportive and disease-modifying drug treatments for anaemia in people with MDS, comparing them to each other, or the standard of care with or without placebo.

Indexed as

AnemiaHematinicsMyelodysplastic SyndromesPhysical Functional PerformanceQuality of LifeErythropoietinHumansRandomized Controlled Trials as TopicErythropoietinHematinics

Identifiers

PMID42396832
PMCPMC13329893

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.